BACKGROUND AND OBJECTIVE:Rivaroxaban is a new oral anticoagulant for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), which has less drug-food interaction than warfarin. We conducted this prospective randomized study to evaluate the metabolic benefits as well as the safety and efficacy with rivaroxaban versus warfarin in patients with NVAF following radiofrequency catheter ablation (RFCA). METHODS:From April to July 2014, 60 patients with NVAF undergoing RFCA were prospectively enrolled in our study. Following RFCA, all patients were randomly assigned to receive rivaroxaban (Group R, n=30) or warfarin (Group W, n=30). Metabolic indices including serum total protein, albumin, globulin, and high-density lipoprotein (HDL) as well as bleeding, stroke, and systemic thromboembolism events were evaluated and compared during follow-up after 15, 30, 60, and 90 d of RFCA procedure. RESULTS:Serum total protein, albumin, globulin, and HDL levels were all significantly elevated at each follow-up stage in Group R when compared to the baseline (P<0.05 respectively). In Group W, the metabolic indices decreased at first and then had an increasing trend. There were no deaths or thromboembolic complications in each group. The prevalence of total bleeding complications was similar between Group R and Group W (11/30, 36.7% vs. 10/30, 33.3%, P=0.79). CONCLUSIONS:Patients with NVAF receivingrivaroxaban after RFCA procedures appear to benefit from a metabolic perspective compared with warfarin, providing practical clinical reference for the choice of the anticoagulant. Rivaroxaban seems to be as safe and effective in preventing thromboembolic events as warfarin for these patients.
RCT Entities:
BACKGROUND AND OBJECTIVE:Rivaroxaban is a new oral anticoagulant for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), which has less drug-food interaction than warfarin. We conducted this prospective randomized study to evaluate the metabolic benefits as well as the safety and efficacy with rivaroxaban versus warfarin in patients with NVAF following radiofrequency catheter ablation (RFCA). METHODS: From April to July 2014, 60 patients with NVAF undergoing RFCA were prospectively enrolled in our study. Following RFCA, all patients were randomly assigned to receive rivaroxaban (Group R, n=30) or warfarin (Group W, n=30). Metabolic indices including serum total protein, albumin, globulin, and high-density lipoprotein (HDL) as well as bleeding, stroke, and systemic thromboembolism events were evaluated and compared during follow-up after 15, 30, 60, and 90 d of RFCA procedure. RESULTS: Serum total protein, albumin, globulin, and HDL levels were all significantly elevated at each follow-up stage in Group R when compared to the baseline (P<0.05 respectively). In Group W, the metabolic indices decreased at first and then had an increasing trend. There were no deaths or thromboembolic complications in each group. The prevalence of total bleeding complications was similar between Group R and Group W (11/30, 36.7% vs. 10/30, 33.3%, P=0.79). CONCLUSIONS:Patients with NVAF receiving rivaroxaban after RFCA procedures appear to benefit from a metabolic perspective compared with warfarin, providing practical clinical reference for the choice of the anticoagulant. Rivaroxaban seems to be as safe and effective in preventing thromboembolic events as warfarin for these patients.
Authors: Suzanne J Francart; Emily M Hawes; Allison M Deal; Dorothy M Adcock; Robert Gosselin; Cheryl Jeanneret; Kenneth D Friedman; Stephan Moll Journal: Thromb Haemost Date: 2014-01-09 Impact factor: 5.249
Authors: Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof Journal: Europace Date: 2013-05 Impact factor: 5.214
Authors: Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni Journal: Heart Rhythm Date: 2009-07-10 Impact factor: 6.343
Authors: Charlotte Eitel; Julia Koch; Philipp Sommer; Silke John; Simon Kircher; Andreas Bollmann; Arash Arya; Christopher Piorkowski; Gerhard Hindricks Journal: Europace Date: 2013-05-22 Impact factor: 5.214
Authors: Anna E Thalacker-Mercer; Craig A Johnson; Kevin E Yarasheski; Nadine S Carnell; Wayne W Campbell Journal: J Nutr Date: 2007-07 Impact factor: 4.798
Authors: A John Camm; Pierre Amarenco; Sylvia Haas; Susanne Hess; Paulus Kirchhof; Silvia Kuhls; Martin van Eickels; Alexander G G Turpie Journal: Eur Heart J Date: 2015-09-01 Impact factor: 29.983